Details of the Drug Combinations

General Information of This Drug (ID: DM8RLJ5)

Drug Name

Elacestrant DM8RLJ5

Synonyms

RAD-1901; ER-306323; ER-308698; SERMs, Eisai/Radius; Selective estrogen receptor modulators, Eisai/Radius

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[1]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

7 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
RAD-1901 + LY2835219	DCXY87G	LY2835219	Breast Cancer	[2]
RAD-1901 + LY2835219	DC2AU8U	LY2835219	Breast Neoplasms	[3]
RAD-1901 + Alpelisib	DCBLD99	Alpelisib	Breast Cancer	[2]
RAD-1901 + Onapristone	DCC8W8G	Onapristone	Breast Cancer	[4]
RAD-1901 + LY2835219	DCLRU53	LY2835219	Breast Cancer	[5]
RAD-1901 + Everolimus	DCW3UDM	Everolimus	Breast Cancer	[2]
RAD-1901 + Triptorelin	DCMT3F2	Triptorelin	Breast Cancer	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 DrugCom(s)

References

1	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217639.
2	ClinicalTrials.gov (NCT05563220) Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
3	ClinicalTrials.gov (NCT05386108) Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer
4	ClinicalTrials.gov (NCT05618613) Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer
5	ClinicalTrials.gov (NCT04791384) Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
6	ClinicalTrials.gov (NCT05982093) Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer